Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis
Abstract: Objective To summarise the available evidence on the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination, compared with the risk among unvaccinated individuals in the absence of COVID-19 infection. Design Systematic review and meta-analysis. Data sources Elect...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
BMJ Publishing Group
2023
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/17346 |
| Aporte de: |
| Sumario: | Abstract: Objective To summarise the available evidence on the
risk of myocarditis and/or pericarditis following mRNA
COVID-19 vaccination, compared with the risk among
unvaccinated individuals in the absence of COVID-19
infection.
Design Systematic review and meta-analysis.
Data sources Electronic databases (Medline, Embase,
Web of Science and WHO Global Literature on Coronavirus
Disease), preprint repositories (medRxiv and bioRxiv),
reference lists and grey literature were searched from 1
December 2020 until 31 October 2022.
Study selection Epidemiological studies of individuals
of any age who received at least one dose of an mRNA
COVID-19 vaccine, reported a risk of myo/pericarditis and
compared the risk of myo/pericarditis to individuals who
did not receive any dose of an mRNA COVID-19 vaccine.
Data extraction and synthesis Two reviewers
independently conducted screening and data extraction.
The rate of myo/pericarditis among vaccinated and
unvaccinated groups was recorded, and the rate ratios
were calculated. Additionally, the total number of
individuals, case ascertainment criteria, percentage of
males and history of SARS-CoV-2 infection were extracted
for each study. Meta-analysis was done using a randomeffects model.
Results Seven studies met the inclusion criteria, of which
six were included in the quantitative synthesis. Our metaanalysis indicates that within 30-day follow-up period,
vaccinated individuals were twice as likely to develop
myo/pericarditis in the absence of SARS-CoV-2 infection
compared to unvaccinated individuals, with a rate ratio of
2.05 (95% CI 1.49–2.82).
Conclusion Although the absolute number of observed
myo/pericarditis cases remains quite low, a higher risk
was detected in those who received mRNA COVID-19
vaccinations compared with unvaccinated individuals
in the absence of SARS-CoV-2 infection. Given the
effectiveness of mRNA COVID-19 vaccines in preventing
severe illnesses, hospitalisations and deaths, future
research should focus on accurately determining the
rates of myo/pericarditis linked to mRNA COVID-19
vaccines, understanding the biological mechanisms behind these rare cardiac events and identifying those
most at risk. |
|---|